| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H11ClN2O |
| Molecular Weight | 270.714 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(C=CC=C2)C(=O)N1C3=CC=CC=C3Cl
InChI
InChIKey=SFITWQDBYUMAPS-UHFFFAOYSA-N
InChI=1S/C15H11ClN2O/c1-10-17-13-8-4-2-6-11(13)15(19)18(10)14-9-5-3-7-12(14)16/h2-9H,1H3
| Molecular Formula | C15H11ClN2O |
| Molecular Weight | 270.714 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Mecloqualone is a quinazoline-class GABAergic and an analog of methaqualone. It acts as an agonist of the beta subtype of GABAa receptor and induces sedative, hypnotic and anxiolytic effects. Mecloqualone was marketed (mostly in france) under the names Nubrene and Casfen for the treatment of insomnia. Mecloqualone is no longer prescribed because of concerns about its potential for abuse and overdose. In the United States, it is registered as a Schedule-I non-narcotic controlled substance.
